U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 12B-25
NOTIFICATION OF LATE FILING
SEC File Number 000-53232

Form 10-K

For Period Ending: March 31, 2017
  
PART I: REGISTRANT INFORMATION

Full Name of Registrant:  Cantabio Pharmaceuticals Inc.
  
Address of Principal Executive Office:
1250 Oakmead Pkwy
Sunnyvale, CA 94085-4037
(408) 501-8893
 
 PART II: RULES 12B-25(B) AND (C)
 
It is anticipated that the subject Annual Report on Form 10-K will be filed within the next several days.
 
 PART III: NARRATIVE
 
The Registrant has not completed its Annual Report on Form 10-K for the period ended March 31, 2017 due to administrative delays.
 
PART IV: OTHER INFORMATION
 
(1) Name and telephone number of person(s) to contact in regard to this notification
 
Thomas Roger Sawyer: (408) 501-8893
 
(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
 
[X] YES [ ] NO
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
[ ] YES [X] NO
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
 
 
 
 
Cantabio Pharmaceuticals Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
  
 
Cantabio Pharmaceuticals Inc.
 
 
 
 
 
Dated: June 30, 2017
By:
/s/  Thomas Roger Sawyer
 
 
 
Thomas Roger Sawyer
 
 
 
Chief Executive Officer